Anna Mestre Borras
KTH Royal Institute of Technology
Adverse effects can be caused by on-target off-tumor toxicities. Conditional activation of targeted drugs can be achieved by using the tumour microenvironment. The design of therapeutics that are selectively activated by tumor-associated proteases can decrease systemic exposure, improving their efficacy and safety. We generated a collection of prodrugs based on antibody and affibody scaffolds, and an E. coli display platform to discover novel tumour protease substrates.
Patricia Marie Aquino
Bristol Myers Squibb
Optimization and Development of a His-Tagged Protein Purification Workflow for Use and Integration into an Automated High-Throughput Protein Production Platform
This work presents an outline of an optimized high throughput (HT) protein purification and production of recombinant proteins with a 6X-Histidine affinity tag to increase and expand our HT production workflow at Bristol Myers Squibb. The method uses immobilized metal-ion affinity chromatography (IMAC) on magnetic beads. Samples are processed from end-to-end in a 96-well format for full integration into automated systems and instrumentation for expression and purification.